Global Biobetter Market Research Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Biobetter Market Research Report 2024
Biobetters, also known as biosuperiors, are recombinant protein drugs from an identical class as a present set of biopharmaceuticals is not similar to the source. It is neither a wholly novel medicine nor a generic version of an old drug. It is a biological product designed to increase clinical efficacy while also improving tolerance and lowering dosing/administration frequency.
According to Mr Accuracy reports’s new survey, global Biobetter market is projected to reach US$ 1538 million in 2029, increasing from US$ 832 million in 2022, with the CAGR of 9.1% during the period of 2024 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Biobetter market research.
According to the Global Use of Medicines 2024 released by IQVIA Institute, the global drug expenditure in 2022 was about US$1.48 trillion (excluding COVID vaccine and treatment-related expenses), and it is predicted to grow at a rate of 3%-6% in the next few years. In terms of drug expenditure, this number in China was about 166 billion dollars in 2022. It is expected that the expenditure on medicines will increase in the next few years. From the perspective of demand, the trend of population aging, the increase of residents’ wealth and the improvement of health awareness will drive the demand for medicines.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Biobetter market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
F.Hoffmann-La Roche AG
Merck and Co.
Sanofi
SERVIER
Porton Biopharma
Eli Lily and Company
Novo Nordisk
Biogen
CSL Behring GmbH
Teva
Segment by Type
G-CSF Biobetters
Insulin Biobetters
Erythropoietin Biobetters
Monoclonal Antibodies Biobetters
Others
Cancer
Diabetes
Genetic Disease
Neurological Disorders
Others
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Biobetter report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source
According to Mr Accuracy reports’s new survey, global Biobetter market is projected to reach US$ 1538 million in 2029, increasing from US$ 832 million in 2022, with the CAGR of 9.1% during the period of 2024 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Biobetter market research.
According to the Global Use of Medicines 2024 released by IQVIA Institute, the global drug expenditure in 2022 was about US$1.48 trillion (excluding COVID vaccine and treatment-related expenses), and it is predicted to grow at a rate of 3%-6% in the next few years. In terms of drug expenditure, this number in China was about 166 billion dollars in 2022. It is expected that the expenditure on medicines will increase in the next few years. From the perspective of demand, the trend of population aging, the increase of residents’ wealth and the improvement of health awareness will drive the demand for medicines.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Biobetter market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
F.Hoffmann-La Roche AG
Merck and Co.
Sanofi
SERVIER
Porton Biopharma
Eli Lily and Company
Novo Nordisk
Biogen
CSL Behring GmbH
Teva
Segment by Type
G-CSF Biobetters
Insulin Biobetters
Erythropoietin Biobetters
Monoclonal Antibodies Biobetters
Others
Segment by Application
Cancer
Diabetes
Genetic Disease
Neurological Disorders
Others
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Biobetter report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices